Category
ANTI MUSCARINICIS
ANTI MUSCARINICIS
Consistent
Purity
Global-Ready
Molecules
Advanced
Manufacturing
Scalable
Production
Partnership
Support
Solifenacin Succinate API has been developed by ASANA Pharmaceutical as part of its urological and neuromodulator API portfolio. Solifenacin Succinate API, listed under CAS number 242478-38-2, is an antimuscarinic agent used in the treatment of overactive bladder by reducing urinary urgency, frequency, and incontinence.
ASANA Pharmaceutical specializes in the development and production of high-purity antimuscarinic APIs such as Solifenacin Succinate. With expertise in urological therapeutics and receptor-targeting compounds, ASANA ensures global regulatory alignment, formulation-ready quality, and robust supply for clients across North America, Europe, and Asia.
ASANA Pharmaceutical collaborates with clinical researchers, formulation scientists, and regulatory partners to advance therapies in urology and bladder health. Solifenacin Succinate [CAS No. 242478-38-2] is a selective muscarinic receptor antagonist used in the treatment of overactive bladder by reducing urinary urgency, frequency, and incontinence. It is a key product in ASANA’s bladder control and neuromodulation API portfolio. As demand grows for targeted, quality-of-life therapies, ASANA remains committed to delivering:
Solifenacin Succinate API are available on public databases such as Wikipidia!